The Factors Affecting Bone Density in Cirrhosis

Authors Information
Article Notes and Dates
To Cite : Hajiabbasi A, Shafaghi A, Fayazi H S, Shenavar Masooleh I, Hedayati Emami M H, et al. The Factors Affecting Bone Density in Cirrhosis, Hepat Mon. 2015 ;15(4):e26871. doi: 10.5812/hepatmon.15(4)2015.26871.
Copyright: Copyright © 2015, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Felecia C, David D. Pathogenesis of osteoporosis Rheumatology. 2011;
  • 2. Lane NE. Kelley's Textbook of Rheumatology. 2013; : 1660-79
  • 3. Bringhust FR, Demay MB, Krane SM, Konenberg HM. Harrison's Principles of Internal Medicine. 2012; : 3082-95
  • 4. Luxon BA. Bone disorders in chronic liver diseases. Curr Gastroenterol Rep. 2011; 13(1): 40-8[DOI][PubMed]
  • 5. Guanabens N, Pares A. Liver and bone. Arch Biochem Biophys. 2010; 503(1): 84-94[DOI][PubMed]
  • 6. Soylu AR, Tuglu C, Arikan E, Yetisyigit T, Kunduracılar H, Koker IH, et al. The Role of Serum Cytokines in the Pathogenesis of Hepatic Osteodystrophy in Male Cirrhotic Patients. Gastroenterol Res Pract. 2012; 2012[DOI]
  • 7. Goral V, Simsek M, Mete N. Hepatic osteodystrophy and liver cirrhosis. World J Gastroenterol. 2010; 16(13): 1639-43[PubMed]
  • 8. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002; 50 Suppl 1-9[PubMed]
  • 9. Lewiecki EM, Rosen CJ. Overview of dual-energy x-ray absorptiometry. 2013;
  • 10. Ghany MG, Hoofnagle JH. Harrison's Principles of Internal Medicine. 2012; : 2520-6
  • 11. Moradzadeh K, Larijani B, Keshtkar AA, Hossein-Nezhad A, Rajabian R, Nabipour I, et al. Normative values of vitamin D among Iranian population: a population based study. In J Osteoporos Metab Disord . 2008; 1(1): 8-15[DOI]
  • 12. Fahimi S, Pharoah P. Reducing salt intake in Iran: priorities and challenges. Arch Iran Med. 2012; 15(2): 110-2[PubMed]
  • 13. Country profile Iran. 2011;
  • 14. WHO Report on the Global Tobacco Epidemic, 2013. Country profile. Iran (Islamic Republic of). 2013;
  • 15. Irani AD, Poorolajal J, Khalilian A, Esmailnasab N, Cheraghi Z. Prevalence of osteoporosis in Iran: A meta-analysis. J Res Med Sci. 2013; 18(9): 759-66
  • 16. Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl. 2004; 10(5): 648-53[PubMed]
  • 17. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int. 2001; 69(6): 321-6[PubMed]
  • 18. Loria I, Albanese C, Giusto M, Galtieri PA, Giannelli V, Lucidi C, et al. Bone disorders in patients with chronic liver disease awaiting liver transplantation. Transplant Proc. 2010; 42(4): 1191-3[DOI][PubMed]
  • 19. Alcalde Vargas A, Pascasio Acevedo JM, Gutierrez Domingo I, Garcia Jimenez R, Sousa Martin JM, Ferrer Rios MT, et al. Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation. Transplant Proc. 2012; 44(6): 1496-8[DOI][PubMed]
  • 20. lindsay R, Cosman F. Harrison's Principles of Internal Medicine. 2012; : 3120-35
  • 21. Giouleme OI, Vyzantiadis TA, Nikolaidis NL, Vasiliadis TG, Papageorgiou AA, Eugenidis NP, et al. Pathogenesis of osteoporosis in liver cirrhosis. Hepatogastroenterology. 2006; 53(72): 938-43[PubMed]
  • 22. Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology. 2001; 33(1): 301-7[DOI][PubMed]
  • 23. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest. 1995; 95(6): 2581-6[DOI][PubMed]
  • 24. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010; 52(4): 605-13[DOI][PubMed]
  • 25. Teneva BH. Pathogenesis and assessment of renal function in patients with liver cirrhosis. Folia Med (Plovdiv). 2012; 54(4): 5-13[PubMed]
  • 26. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis. 2003; 41(2): 269-78[DOI][PubMed]
  • 27. Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med. 1987; 82(5): 945-52[PubMed]
  • 28. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet. 2003; 362(9398): 1819-27
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check